- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Entero Healthcare reported strong Q2 FY26 results. Revenue grew 20.8% YoY to ₹1,571 Cr, with EBITDA up 46% to ₹62 Cr (4% margin) and PAT up 41% to ₹37 Cr (2.3% margin). Net working capital days improved to 63.
Management remains confident in FY26 guidance, projecting over ₹100 Cr in operating cash flow and 30% revenue growth, boosted by H2 momentum. A key focus is MedTech, targeting ₹1,000 Cr in new acquisitions for FY26. These MedTech additions, offering higher growth and double-digit margins, are expected to significantly enhance overall company margins to 4.5-4.75%. The company highlighted its expanding national network and tech-driven efficiencies. Sentiment is confident about accelerated growth and margin expansion.